Endocrine Abstracts

Introduction: Dysthyroid orbitopathy is an autoimmune disorder that occurs in the context of dysthyroidism. corticosteroid therapy is the main therapeutic option recommended by EUGOGO for the management of moderate and severe active forms.

Goal of the Study: Describe the clinical, para-clinical and evolutionary characteristics of dysthyroid orbitopathy treated by bolus corticosteroid therapy

Materials and Methods: This is a descriptive and analytical study including all patients with dysthyroidism associated with orbitopathy with an activity score (EUGOGO) ≥ 3. The protocol consists of the IV infusion of 6 boluses of 500 mg of methylprednisone per week followed by 6 others of 250 mg per week with a cumulative dose not exceeding 7.5g

Results: Our study involved 53 patients with an average age of 44.5 years. With a male predominance of 62%. The average evolution of the orbitopathy was 15.7 months. The most common etiology was Graves’ disease in 96% of cases. Among our patients 18 were active smokers. The majority of patients were in biological euthyroidism. The average activity score was 4.9. In our series, 52% of patients had grade 2 proptosis and 48% had grade 3. Optic nerve damage was objectified in 6 patients. On the therapeutic level, 38 had received the entire protocol while 7 patients had interrupted before the appearance of the effects After 1 month, all the patients who had completed the protocol had reported a marked improvement with an average drop in the activity score of 3.5 which

Conclusion: Our study showed the effectiveness of corticosteroid therapy in the management of active dysthyroid orbitopathies at the cost of acceptable intolerance.